Close Menu

NEW YORK – Gilead Sciences and Second Genome have launched a collaboration to identify biomarkers linked to clinical response in up to five of Gilead's pipeline compounds in inflammation, fibrosis, and other diseases. The team aims to also identify potential targets and drug candidates for treating inflammatory bowel disease (IBD).

As part of the project, South San Francisco-based Second Genome will use its Microbiome Analytics Platform to identify novel biomarkers associated with clinical responses to Gilead's investigational medicines.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.